- Home
- BYAH vs TOVX Comparison
BYAH vs TOVX Comparison
Compare BYAH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYAH | TOVX |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 7.3M |
| IPO Year | 2024 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BYAH | TOVX |
|---|---|---|
| Price | $0.17 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 249.3K | ★ 10.6M |
| Earning Date | 02-06-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,768,120.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.65 | N/A |
| 52 Week Low | $0.14 | $0.17 |
| 52 Week High | $41.49 | $2.03 |
Technical Indicators
Market Signals| Indicator | BYAH | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.78 |
| Support Level | N/A | $0.19 |
| Resistance Level | N/A | $0.26 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 60.57 |
Price Performance
Historical ComparisonAbout BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.